Comerica Securities’s Takeda Pharmaceutical TAK Stock Holding History

Comerica Securities’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-656	Closed	-$10.2K	–	1301
2022 Q4	$10.2K	Buy	+656	New	+$9.16K	﹤0.01%	1029

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Comerica Securities's TAK Position: Q1 2023 in Review

Comerica Securities sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 656 shares — an estimated $10.2K sold.

Comerica Securities first reported a position in TAK in Q4 2022 and held it in 1 quarter. The position peaked at $10.2K in Q4 2022. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

Comerica Securities reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 656 Takeda Pharmaceutical shares in Q1 2023, an estimated $10.2K.
Comerica Securities first reported a position in Takeda Pharmaceutical in Q4 2022 and held it in 1 quarter.
Comerica Securities's Takeda Pharmaceutical position peaked at $10.2K in Q4 2022.
300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.